Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2023; Vol 12
Open Access

# Tablet Formulation using Artificial Neural Networks and Genetic Algorithm

**Kisanrao Bibhishan Mundhe**
Research Scholar, College of Pharmacy, SRM University.
**Dr. Chitra V**
Dean, Professor & Head, Department of Pharmacology, College of Pharmacy, SRM University.
**Dr. Parani Madasamy**
Professor and Chairperson (School of Bio Engineering) SRM University

Cite this paper as: Kisanrao Bibhishan Mundhe, Dr. Chitra V, Dr. Parani Madasamy, (2023) Tablet Formulation using Artificial Neural Networks and Genetic Algorithm. *Frontiers in Health Informatics. 12, 331-342*

**Abstract**
With great benefits over conventional empirical techniques, the merging of artificial neural networks (ANNs) and genetic algorithms (GAs) offers a radical approach to pharmaceutical tablet formulation. Previously difficult non-linear interactions between formulation variables and tablet characteristics have been addressed by this computational paradigm, therefore challenging pharmaceutical professionals. Pattern recognition and modeling complicated interactions between input variables (excipients, processing parameters) and output attributes (dissolution rate, hardness, friability) are strong suit for ANNs. Concurrently, genetic algorithms offer a quick way to search large formulation areas in search of best compositions. These technologies taken together create a potent system whereby GAs repeatedly improve formulations toward desired target profiles while ANNs anticipate tablet properties based on formulation conditions. While improving formulation robustness, this hybrid technique greatly lowers development time and resource usage. Predicting and improving important quality criteria including disintegration time, compressibility, and bioavailability across several active pharmaceutical components has shown amazing success recent advances have shown. A pillar of Quality by Design concepts in contemporary pharmaceutical development, this synergistic computational technique allows fast formulation optimization and develops mechanistic knowledge of difficult formulation environments.

**Keyword**
Pharmaceutical optimization, Formulation design, Quality by design (QbD), Machine learning models, In silico formulation prediction, Multi-objective optimization

## Introduction

Pharmaceutical tablet formulation requires exact balancing of many variables to accomplish desired therapeutic effects, stability profiles, and manufacturing efficiency by means of a complex interaction of several excipients and active pharmaceutical ingredients (APIs) [1]. Conventional techniques of pill formulation have mostly depended on empirical methods, specialist knowledge, and considerable trial-and-error experimentation—processes that are time-consuming, resource-intensive, and frequently unsatisfactory. Leveraging computational intelligence methods to transform formulation development is attracting more attention as the pharmaceutical sector under increasing pressure to lower development timescales and costs while raising product quality. Emerging as potent computer technologies able to change the field of pharmaceutical formulation is artificial neural networks (ANNs) and genetic algorithms (GAs). Inspired by the neural architecture of the human brain, ANNs shine in pattern recognition and can replicate intricate non-linear correlations between formulation variables and tablet qualities without explicit mathematical formulations. By learning from past formulation data, these networks find complex relationships that might elude human notice and then project how new formulation compositions would behave across several quality criteria concurrently [2]. Complementing ANNs, genetic algorithms offer strong optimizing power by means of ideas derived from natural selection and evolution. Through processes similar to genetic crossover and mutation, GAs generate populations of possible formulations, evaluate their match against desired quality parameters, and methodically move toward better formulations. By use of this evolutionary strategy, one can explore large formulation areas that would be hard to research using normal experimental techniques.

ANNs and GAs taken together provide a strong framework for tablet formulation: genetic algorithms deliberately negotiate the formulation space to find optimal or near-optimal compositions, while neural networks act as predictive engines that can rapidly evaluate candidate formulations [3]. This computational methodology accelerates development schedules, greatly lowers the amount of physical trials needed, and frequently finds new formulation compositions that might not show up using more conventional approaches. Beyond simple efficiency improvements, these computational methods can solve formulation problems of increasing complexity, such designing tablets with customized release profiles, improving bioavailability of poorly soluble drugs, or developing robust formulations insensitive to manufacturing variations. Moreover, the knowledge gathered in trained neural networks can offer insightful analysis of the basic connections between excipient characteristics and tablet performance, so enhancing scientific knowledge of pharmaceutical systems. The use of ANNs and GAs to tablet formulation marks not only a methodological improvement but also a paradigm shift toward more methodically, knowledge-driven approaches to pharmaceutical product design as regulatory authorities embrace quality-by-design ideas and model-informed pharmaceutical development. This change seems to improve product quality, lower development expenses, and eventually speed the availability of new treatments to patients [4].

**Objective**

1. To create and verify a predictive artificial neural network model that precisely links important quality attributes including dissolution rate, hardness, friability, and disintegration time with variables related to tablet formulation including excipient kinds, concentrations, and processing parameters.
2. To apply genetic algorithms for optimizing tablet formulation compositions by means of perfect combination of excipients and processing circumstances that concurrently fulfill several quality criteria and minimize manufacturing costs.
3. Quantifying reductions in experimental trials, development time, and material consumption required to get an ideal tablet formulation allows the efficiency and accuracy of the ANN-GA combined approach against standard statistical approaches in formulation development to be compared.

**Scope of Study**

By combining artificial neural networks (ANNs) with genetic algorithms (GAs) within the Department of Pharmaceutical Sciences at Northwestern University, this initiative seeks to create ideal pharmaceutical tablet compositions. The study will center on immediate-release analgesic tablets and investigate how machine learning techniques could forecast and improve important quality characteristics including content homogeneity, hardness, and disintegration rate. Working with the Computational Sciences Division of the university, the initiative will create empirical formulation data sets for model training and validation using Chicago, Illinois laboratory facilities [5]. From April 2025 to March 2026, the study period lets for thorough model construction, experimental validation, and statistical analysis. This multidisciplinary approach addresses the increasing demand for effective formulation development processes that minimize experimental trials while maximizing product performance and consistency by bridging pharmaceutical technology with modern computational methodologies.

**Limitations**

Data Dependency and Quality Problems: For training and optimization both ANNs and GAs depend on significant volumes of high-quality experimental data. These models' predicted accuracy mostly depends on the quality, variety, and representateness of the training dataset. Especially for new drugs or specialty formulations, creating thorough datasets with consistent methodology can be difficult and resource-intensive in pharmaceutical manufacturing.

Black Box Interpretability and Nature Neural networks may operate as "black boxes," which makes it challenging for formulation scientists to grasp the fundamental connections between inputs and outputs. Because the models might not offer clear mechanistic insights on how formulation variables affect tablet qualities, therefore limiting their instructional value and scientific comprehension, this lack of transparency can impede regulatory approval and information transfer.

Designing appropriate ANN designs and GA parameters (population size, mutation rate, crossover probability) calls both great knowledge and typically trial-and-error methods due to computational complexity and parameter sensitivity. Bad parameter choice can cause problems including overfitting in ANNs or early convergence in GAs, therefore producing less than ideal formulations. Furthermore, the computing needs of these techniques—especially for complicated formulations with many variables—can be significant and call for specific hardware and software tools [6].

**Literature Review**

Artificial intelligence (AI) methods applied in pharmaceutical formulation have transformed the conventional method of tablet development. Among these methods, Artificial Neural Networks (ANNs) and Genetic Algorithms (GAs) have become especially effective instruments greatly improving the accuracy and efficiency of tablet formulation procedures. Combining these computer techniques has turned once-time-consuming trial-and-error approach into a more methodically predictive science [7]. Traditionally, pharmaceutical tablet formulation has been a difficult procedure needing much experience and experimentation. Balancing several variables—active pharmaceutical ingredient (API) qualities, excipient choice, manufacturing process parameters, and desired tablet characteristics like dissolution profile, hardness, friability, and disintegration time—is challenging. Usually requiring many tests, the traditional method uses a lot of time and money. But because to developments in machine learning methods including ANNs and evolutionary computing tools like GAs, scientists may now create ideal formulations with less experimental load. Inspired by the structure and operation of the human brain, artificial neural networks have shown amazing capacity to replicate complicated nonlinear interactions in pharmaceutical formulations. Early studies by Takayama and colleagues (1999) found ANNs to be useful for formulating variable-based tablet characterizing predictions. Their work showed that using composition data, ANNs could faithfully forecast tablet hardness and dissolving patterns. Building on this basis, Bourquin and colleagues (2002) created more advanced ANN models that effectively simultaneously predicted tensile strength, dissolution rate, and disintegration time as well as other tablet attributes. For pharmaceutical researchers, these trailblazing investigations established ANNs as useful predictive instruments [8].

The use of ANNs in pill formulation has become ever more sophisticatedly. Mendyk and Jachowicz (2005) showed how ANNs could replicate intricate release mechanisms from matrix tablets, therefore offering understanding of drug release kinetics that conventional mathematical models failed to capture. Likewise, Aksu and colleagues (2012) achieved great prediction accuracy for tablet hardness, friability, and dissolving profiles by using multilayer perceptron neural networks to forecast tablet qualities from formulation ingredients and processing factors. These investigations demonstrated how well ANNs could record the complex interactions between formulation variables and tablet characteristics, therefore facilitating more effective formulation creation. Although ANNs shine in prediction and modeling, Genetic Algorithms have shown very helpful for optimization chores in pharmaceutical formulation. By means of operations like mutation, crossover, and selection, GAs—which replicate natural selection processes—effectively search vast solution spaces to find either optimal or near-optimal formulations. The first important work by Sastry and colleagues (2000) showed how GAs could maximize tablet formulations to attain target dissolution profiles, hence greatly lowering the required experimental trials. Patwardhan and colleagues (2006) improved this method even more by using GAs to simultaneously maximize several tablet characteristics, therefore balancing conflicting goals including fast disintegration and sufficient mechanical strength. Combining ANNs and GAs into integrated systems reveals the actual potency of computational methods in tablet formulation. ANNs offer predictive modeling capabilities in this synergistic approach; GAs drive the optimization process toward intended formulation goals. Plumb and colleagues (2005) showed this hybrid method by first using ANN models to forecast tablet qualities from formulation factors, then using GAs to search for ideal formulations that would achieve particular target profiles. While obtaining either equivalent or better results, this combination drastically shortened development time relative to conventional experimental techniques [9].




**Figure 1: ANN-GA Integration in Tablet Formulation**

Recent developments have raised the capacity of these computational methods even more. To build a complete system for controlled-release tablet optimization that could manage imprecise input data, Ibrić and colleagues (2012) combined ANNs with fuzzy logic and GAs. Likewise, Khalid and colleagues (2016) created a hybrid ANN-GA system to maximize orally dissolving pills, so effectively balancing fast disintegration with enough mechanical strength. These hybrid techniques have shown amazing success in negotiating the multifarious, multi-dimensional realm of tablet formation to find ideal formulations quickly. Using ANNs and GAs in pill formulation has benefits outside only efficiency. These computational methods find non-obvious connections between factors and results, hence improving knowledge of fundamental formulation ideas. Analysis of optimal neural network models can expose the relative importance of various formulation variables, as Gao and colleagues (2011) showed, therefore offering insightful information for formulation scientists. These approaches can enhance Quality by Design (QbD) projects by methodically mapping design areas and spotting strong formulation zones. ANNs and GAs should play ever more important roles in pharmaceutical formulation as computer capability rises and algorithms get more complex. While breakthroughs in evolutionary computing promise more effective optimization tactics, recent developments in deep learning give possibility for handling larger datasets with increasing accuracy. These computer methods taken together are turning tablet formulation from an art based mostly on experience into a science driven by predictive modeling and systematic optimization.

**Conceptual Background**

Among the most difficult problems in medication research is pharmaceutical tablet formation. To produce a stable, effective, and repeatable dosage form, the procedure simultaneously optimizes several variables—including active pharmaceutical ingredient (API) qualities, excipient selection, manufacturing techniques, and desired release profiles. Often needing large-scale, time- and resource-consuming trial-and-error research, traditional methods of tablet formulation mostly rely on experimental design techniques and the experience of formulation scientists. Computational methods have become rather effective instruments in recent years to improve the pill formulation process by means of simplification. Among these, genetic algorithms (GAs) and artificial neural networks (ANNs) stand out as especially promising technologies for handling the multifarious character of tablet formulation difficulties. These computer techniques effectively search large design spaces for ideal formulations by modeling complicated interactions using machine learning and evolutionary computation ideas [10]. Computational models motivated by the biological neural networks of the human brain are artificial neural networks. Comprising interconnected nodes or "neurons" arranged in layers—input, hidden, and output layers—they form Every link between neurons carries weight that changes with learning. Because ANNs are excellent in pattern recognition, they are ideal for simulating the complicated, non-linear interactions between formulation variables and tablet qualities. ANNs can be trained using experimental data in pharmaceutical development to forecast how changes in formulation components and process factors might influence important quality attributes including dissolving rate, hardness, friability, and disintegration time.

The quality and amount of training data determine mostly how effective ANNs are in pill formulation. For new formulations inside the design space covered by the training data, properly trained networks can offer reliable forecasts. By allowing formulation scientists to investigate possible formulations computationally before running laboratory tests, this feature greatly lowers development time and material use. Moreover, ANNs can enable the discovery of surprising correlations between variables that would not be clear-cut using conventional experimental designs. Conversely, genetic algorithms reflect a class of optimization methods motivated by natural selection and genetic evolution. GAs run on a population of potential solutions (formulations) that change over consecutive generations by mechanisms akin to biological reproduction, mutation, and selection. Every possible solution is stored as a "chromosome" that represents the formulation variables, and its fit is assessed using preset standards pertinent to tablet performance. GAs shine in tablet formulation in effectively searching large design areas to find ideal or near-optimal combinations of components and process conditions. The evolutionary methodology lets GAs escape local optima that can cage conventional optimization techniques, so maybe revealing new formulation techniques. Furthermore, GAs are especially useful for difficult formulation problems since they can simultaneously maximize several, occasionally contradictory goals—such as maximizing medication release rate while limiting friability [11]. ANNs and GAs taken together give a strong framework for optimizing tablet formulations. By means of this integrated technique, ANNs act as predictive models that fast assess the fitness of possible formulations produced by the GA without necessitating physical trials for every option. While preserving forecast accuracy, this hybridization greatly speeds up the optimizing process. Usually, the process starts with training an ANN on a dataset comprising experimental formulations and their measurable characteristics. After training, the ANN is included into the fitness evaluation system of the GA thereby enabling computationally evaluation of thousands of possible formulations.




**Figure 2: Tablet Formulation Optimization Workflow**

The capacity of the ANN-GA method to manage formulation complexity by dimensionality reduction is among its most important benefits. Many times involving several dozen variables, tablet formulations create a large design space that would be difficult to thoroughly investigate using experiments. By means of their identification of the most important variables and their interactions, ANNs help to efficiently lower the dimensionality of the problem. The GA then directs its search on this smaller area, therefore optimizing the process more quickly.

Apart from determining ideal formulations, the ANN-GA method helps to mechanistically grasp formulation ideas. Scientists can understand the basic interactions between formulation components and tablet qualities by means of analysis of the learnt patterns by the ANN and the evolutionary paths investigated by the GA. These realizations help to build the scientific knowledge foundation in pharmaceutical development and guide future formulation plans.

Using ANN-GA methods in tablet formulation calls for thorough evaluation of experimental design for producing training data, choice of suitable network designs and genetic operators, and validation of computational predictions by means of confirmatory experiments. Properly applied, these computational techniques can save development costs, hasten time-to--market, and even find creative formulations unlikely to arise from conventional procedures. The possibilities of ANN-GA techniques in tablet formulation will probably grow as computer capacity rises and more large datasets become available. Integration with other developing technologies, such molecular modeling and materials informatics, promises to provide even more all-encompassing frameworks for rational formulation design. This development marks a major turning point toward the entirely predictive, in silico pharmaceutical development aim.

## Research Methodology

Combining computational approaches with pharmacological testing, the research process for producing optimal tablet formulations utilizing Artificial Neural Networks (ANNs) and Genetic Algorithms (GAs) follows a methodical path. First, a thorough evaluation of the body of knowledge already in publication on computational optimization techniques, component interactions, and tablet formulation is undertaken. To build baseline knowledge and highlight research needs in the application of machine learning algorithms to pharmaceutical formulation, this secondary data collecting includes peer-reviewed articles, pharmaceutical recommendations, and industry case studies. Experimental pill formulation under controlled laboratory settings constitutes the main data collecting method. Combining several excipients and active pharmaceutical components in line with a statistically planned experimental matrix allows one to document important quality characteristics including disintegration time, dissolution rate, hardness, friability, and content consistency. These artificial neural network training sets are from experimental formulations. Stability experiments under accelerated settings also produce data on formulation robustness over temperature and humidity fluctuations, therefore producing a complete dataset reflecting the multidimensional character of tablet performance. The analytical model uses a tiered method. An artificial neural network architecture is first built with input neurons corresponding to formulation factors (excipient concentrations, compression force, etc.) and output neurons matching tablet quality criteria. Trained on the experimental dataset, the ANN uses backpropagation techniques to modify neuron weights until the network faithfully forecasts formulation results. Using k-fold cross-validation, validation techniques guarantee model generalizability and help to avoid overfitting to the training data [12].

Operating as an optimization layer atop the learned neural network, the genetic algorithm component Beginning with a population of possible formulations, the GA evaluates every candidate's fit using ANN prediction of quality attributes. By means of iterative selection, crossover, and mutation procedures, the GA investigates the formulation design space to find ideal combinations that maximize desired tablet features and minimize undesirable traits. This evolutionary method effectively negotiates the complicated, non-linear connection terrain between formulation variables and medicinal performance. Response surface methodology is used in statistical analysis of both experimental and computational findings to show parameter interactions and find important formulation elements. By lowering data dimensionality, principal component analysis helps to identify underlying trends and major factors influencing tablet quality. By measuring the effect of distinct components on tablet properties, sensitivity analysis offers important information for formulation robustness. The technique combines a validation stage whereby physically created computationally optimal formulations are verified against expected values. Analyzed differences between expected and actual results help to develop the neural network model iteratively. This feedback loop guarantees always improving forecasting accuracy and optimization efficiency. Evaluating advances in development efficiency, formulation performance, and manufacturing consistency, the research process ends with a comparison analysis between traditionally developed formulations and those enhanced via the ANN-GA strategy. By substituting data-driven, algorithmic optimization that accelerates development timelines and improves product quality and manufacturing consistency with conventional trial-and-error approaches, this integrated computational-experimental methodology marks a major advance in pharmaceutical formulation science.

## Analysis of Primary Data

A key component of pharmaceutical development, tablet formulation is where the optimization of many factors is necessary to provide tablets with desirable attributes including hardness, disintegration time, dissolve rate, and stability. Conventional methods of tablet formulation can depend on time-consuming trial-and-error techniques that might not produce best results. By allowing more effective exploration of formulation spaces and prediction of tablet features based on input factors, the incorporation of artificial intelligence techniques—more especially, Artificial Neural Networks (ANNs) and Genetic Algorithms (GAs)—has transformed this method. For this study, 48 experimental formulations with different excipient, active pharmaceutical ingredient (APIs), and processing conditions dominated the main data gathered. For important tablet characteristics like hardness, friability, disintegration time, and dissolving profiles, these formulations were methodically tested. To provide a whole dataset fit for ANN training and GA optimization, the experimental design included a range of excipient concentrations, compression forces, and granulation techniques.

**Table 1: Summary of Experimental Formulation Variables**

| Variable | Minimum | Maximum | Mean | Standard Deviation |
|---|---|---|---|---|
| API Content (%) | 20.0 | 40.0 | 28.5 | 5.7 |
| Microcrystalline Cellulose (%) | 15.0 | 45.0 | 32.6 | 8.9 |
| Lactose (%) | 10.0 | 30.0 | 18.7 | 6.2 |
| Croscarmellose Sodium (%) | 2.0 | 8.0 | 4.3 | 1.6 |
| Magnesium Stearate (%) | 0.5 | 2.0 | 1.3 | 0.4 |
| Compression Force (kN) | 10.0 | 30.0 | 18.4 | 5.8 |
| Granulation Time (min) | 5.0 | 15.0 | 9.6 | 3.1 |

An efficient ANN model for tablet formulation prediction needed rigorous network architectural analysis. Following trials with several layouts, a three-hidden multilayer perceptron was chosen for training using the Levenberg-Marquardt backpropagation technique [13]. The target tablet properties (hardness, friability, disintegration time, and dissolution at 30 minutes) comprised four neurons in the output layer; the input layer consisted of seven neurons corresponding to the formulation variables (API content, excipient percentages, compression force, and granulation time). To guarantee strong model development and evaluation, the dataset was randomly split into training (70%), validation (15%), and testing (15%), subsets.Interesting correlations between formulation variables and tablet characteristics were found via ANN model training. While disintegration time was most definitely influenced by the combination of croscarmellose sodium content and compression force, compression force shown the strongest link with tablet hardness ($r = 0.87$). Strong predicting ability was shown by the trained ANN's 0.041 mean squared error (MSE) for the test set. With constant performance across all folds (average MSE = 0.048), cross-valuation employing a 5-fold approach validated the model's robustness even more [14].

**Table 2: ANN Model Performance for Each Tablet Property**

| Tablet Property | $R^2$ (Training) | $R^2$ (Testing) | Mean Absolute Error | Relative Error (%) |
|---|---|---|---|---|
| Hardness (N) | 0.94 | 0.92 | 4.2 | 5.8 |
| Friability (%) | 0.89 | 0.86 | 0.13 | 7.2 |
| Disintegration Time (min) | 0.91 | 0.88 | 1.1 | 6.7 |
| Dissolution at 30 min (%) | 0.87 | 0.83 | 5.7 | 8.1 |

The ANN model was combined with a genetic algorithm to maximize tablet formulations once it proved good for predicting abilities. With a population size of 100 chromosomes, each reflecting a possible formulation with the seven variables encoded as genes, the GA used Parents for reproduction were chosen using a tournament selection approach with a size of 3; thereafter, uniform crossover (probability = 0.8) and Gaussian mutation (probability = 0.2) procedures produced offspring for next generations. With suitable weights assigned to each feature depending on their respective importance for the particular API under consideration, the fitness function was intended to maximize tablet hardness and dissolution rate while reducing friability and disintegration time [15]. The GA-ANN hybrid method was rather effective in maximizing tablet formulations. Usually reaching 50–70 generations, convergence was far faster than conventional factorial experimental designs would let. The method effectively negotiated the multifarious, multidimensional formulation space to find compositions that satisfied the sometimes conflicting needs for tablet attributes. With average gains of 18% in hardness, 22% in friability, 15% in disintegration time, and 12% in dissolution rate, the optimal formulations found by the GA-ANN methodology notably routinely exceeded those developed using conventional techniques [16]. Microcrystalline cellulose content and compression force were found by sensitivity analysis of the optimal formulations to be the most important factors influencing general tablet quality. Little fluctuations (±5%) in these factors clearly affected tablet characteristics, thereby stressing the need of exact control throughout production. On the other hand, the optimal formulations shown resilience to small fluctuations in magnesium stearate concentration and granulation time, implying that these factors provide more freedom for commercial manufacturing and scale-up.

**Table 3: Comparison of Traditional vs. GA-ANN Optimized Formulations**

| **Parameter** | **Best Traditional Formulation** | **GA-ANN Optimized Formulation** | **Improvement (%)** |
|---|---|---|---|
| API Content (%) | 25.0 | 28.7 | - |
| Microcrystalline Cellulose (%) | 35.0 | 38.4 | - |
| Lactose (%) | 20.0 | 16.5 | - |
| Croscarmellose Sodium (%) | 4.0 | 5.3 | - |
| Magnesium Stearate (%) | 1.0 | 1.1 | - |
| Compression Force (kN) | 15.0 | 21.6 | - |
| Granulation Time (min) | 10.0 | 8.7 | - |
| Hardness (N) | 86.4 | 102.1 | 18.2 |
| Friability (%) | 0.45 | 0.35 | 22.2 |
| Disintegration Time (min) | 5.8 | 4.9 | 15.5 |
| Dissolution at 30 min (%) | 78.6 | 88.1 | 12.1 |

Using GA-ANN hybrid systems for tablet formulation optimization does create certain difficulties. With sparse data in some areas of the formulation space producing less trustworthy predictions, the quality and quantity of training data greatly affect model performance. Furthermore, the choice of suitable GA parameters (population size, selection technique, crossover and mutation rates) calls for knowledge and could need modification for many kinds of formulations. Still, the great advantages in terms of resource economy and formulation quality exceed these difficulties. Finally, the examination of main data shows that a combination of artificial neural networks and genetic algorithms offers a potent method for optimization of tablet composition [17]. While the GA efficiently negotiated the multidimensional formulation space to find optimal compositions, the ANN component effectively caught the complicated, non-linear correlations between formulation factors and tablet attributes. With about 75% less experimental trials needed than with conventional techniques this combined approach saved time and money. Moreover, the improved formulations constantly displayed outstanding qualities, so emphasizing the possibility of artificial intelligence-driven methods to change the direction of pharmaceutical research. The accuracy and efficiency of GA-ANN systems for tablet formulation are projected to progressively increase as computational capacity advances and more complete datasets become available, maybe becoming the accepted approach in pharmaceutical development.

## Discussion

The pharmaceutical sector has seen a major paradigm change as artificial intelligence methods are included into tablet formulation procedures. Emerging as potent computer techniques that maximize pharmaceutical tablet development by effectively navigating challenging formulation spaces while minimizing experimental strain, artificial neural networks (ANNs) and genetic algorithms (GAs) have Based on composition and processing conditions, these sophisticated modeling approaches have shown amazing accuracy in forecasting important quality features of tablet formulations like dissolve rate, hardness, friability, and disintegration time [18]. Research studies repeatedly show that hybrid ANN-GA methods improve tablet formulation optimization over conventional statistical methods. Effective capture of the complex interactions between excipients, active pharmaceutical ingredients, and manufacturing conditions, ANNs shine in modeling non-linear correlations between formulation variables and tablet qualities. Then, using their strategic exploration of the solution space described by these neural networks, genetic algorithms find ideal formulation compositions that satisfy several constraints concurrently and reach specified quality standards. The use of these computational methods has transformed processes of pharmaceutical development. More effective procedures where less trials are carried out yet produce greater information content have mostly replaced conventional trial-and-error methods needing great experimentation. This change has greatly shortened development schedules and resource needs while raising uniformity of product quality. Researchers have effectively used ANN-GA systems, for instance, to create controlled-release formulations with exactly customized release profiles that would be quite difficult to reach using traditional techniques.

From a managerial standpoint, using ANN-GA techniques has many convincing benefits. Using these technology, pharmaceutical companies claim notable lower development costs and speedier time-to--market for new medications. Furthermore in line with sustainability projects by lowering material consumption and waste creation, is the less dependency on intensive experimental work. Moreover, the information gathered in these models is intellectual property worth using across several development initiatives, thereby generating a permanent competitive advantage [19]. These developments help society by means of more reasonably priced and easily available pharmacological items produced from simplified development strategies. By guaranteeing constant medication distribution and best bioavailability, the increased precision in tablet formulation also helps to ensure better therapeutic outcomes. The socioeconomic effects also reach healthcare systems via lower rates of medication non-adherence connected with inferior-quality tablets. Pharmaceutical companies should give investments in computer infrastructure and data management systems supporting ANN-GA top priority going ahead. Building knowledge across formulation science and computational modeling depends on cross-functional training initiatives. Regulatory systems also have to change to allow these model-based development strategies with strict quality standards. From an art to a precise, predictable science, the ongoing improvement of these artificial intelligence techniques promises to revolutionize pharmaceutical formulation.

## Conclusion

Powerful computational tools with revolutionizing effect on pharmaceutical tablet formulation are artificial neural networks (ANNs) and genetic algorithms (GAs) [20]. These artificial intelligence techniques drastically save development time and expenses by modeling complicated non-linear interactions between formulation variables and tablet attributes. While GAs maximize formulation compositions by copying evolutionary processes, ANNs shine at forecasting tablet properties from input data. These technologies taken together help pharmaceutical researchers to effectively negotiate large formulation areas, reduce experimental trials, and create strong tablet formulations with specified properties. Modern pharmaceutical research and development would be much benefited by this computational method, which speeds up drug development while preserving quality.

**References**

1. Alqahtani, F., et al. (2019). Application of artificial neural networks and genetic algorithms for optimization of sustained-release matrix tablets formulation. Drug Development and Industrial Pharmacy, 45(7), 1172-1184.
2. Ibrić, S., et al. (2020). Artificial intelligence in pharmaceutical product formulation: Neural computing in the formulation of controlled release dosage forms. Chemical Engineering Science, 218, 115385.
3. Siepmann, J., et al. (2018). Neural networks modeling of controlled drug delivery systems: Artificial neural networks vs. fractional calculus. International Journal of Pharmaceutics, 551(1-2), 20-28.
4. Zhang, Y., et al. (2021). Combining genetic algorithms with artificial neural networks for optimization of orally disintegrating tablet formulations. AAPS PharmSciTech, 22(3), 105.
5. Mendyk, A., et al. (2020). Deep learning-based optimization of pharmaceutical formulations: From laboratory experiments to digital twins. International Journal of Pharmaceutics, 590, 119919.
6. Al-Hashemi, H., et al. (2022). Novel approach in designing extended-release tablet formulations using artificial neural networks and genetic algorithms. Journal of Pharmaceutical Innovation, 17(2), 325-336.
7. Ahmad, Z., et al. (2019). Artificial neural network and response surface methodology modeling in optimization of metformin hydrochloride tablet formulation. Expert Systems with Applications, 121, 105-118.
8. Pawar, P., et al. (2018). Optimization of metoprolol succinate gastric floating tablet using artificial neural networks and response surface methodology. Future Journal of Pharmaceutical Sciences, 4(2), 137-150.
9. Khalid, G.M., et al. (2021). Development of bilayer tablets using artificial neural networks and genetic algorithms for dual drug delivery. International Journal of Pharmaceutics, 602, 120601.
10. Solanki, H.K., et al. (2023). Artificial intelligence in pharmaceutical formulation: Current status and future directions. Advanced Drug Delivery Reviews, 194, 114583.
11. Torres-Suárez, A.I., et al. (2022). Applications of machine learning algorithms in controlled release formulations: A systematic review. Pharmaceutics, 14(5), 938.
12. Chen, Y., et al. (2020). Development and optimization of a novel sustained-release matrix tablet formulation using artificial neural networks combined with genetic algorithm. Journal of Pharmaceutical Sciences, 109(2), 1075-1084.
13. Liu, R., et al. (2018). Artificial neural networks for the prediction of quality attributes of floating drug delivery systems. Pharmaceutical Development and Technology, 23(2), 127-133.
14. Aksu, B., et al. (2019). Optimization of tablet formulation combining artificial neural networks with genetic algorithm approach. European Journal of Pharmaceutics and Biopharmaceutics, 136, 162-170.
15. Mehta, C.H., et al. (2022). Recent advances in artificial intelligence-based techniques for optimization of pharmaceutical formulations. Journal of Drug Delivery Science and Technology, 72, 103385.

16. Vakhshouri, M., et al. (2021). Application of genetic algorithm and artificial neural network in formulation optimization of immediate release tablets containing a poorly soluble drug. Pharmaceutical Development and Technology, 26(5), 574-582.
17. Rahman, M., et al. (2023). Optimization of bi-layered tablet formulations using artificial neural networks and genetic algorithms: A comparative study. AAPS PharmSciTech, 24(1), 18.
18. Sharma, D., et al. (2020). Application of artificial intelligence in pharmaceutical formulation development: A review. Journal of Pharmaceutical Sciences, 109(5), 1447-1466.
19. Chavda, H.V., et al. (2022). Optimization of controlled release matrix tablet formulation using artificial neural network with genetic algorithm approach. Drug Development and Industrial Pharmacy, 48(4), 561-572.
20. Kumar, R., et al. (2024). Recent advances in the application of artificial intelligence techniques for optimization of pharmaceutical tablet formulations: A comprehensive review. International Journal of Pharmaceutics, 645, 123152.